Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
AAP Newsroom on MSN
Cheaper diabetes drug halted by AstraZeneca court win
Consumers will have to wait longer for a more affordable diabetes and heart failure drug after pharmaceutical giant ...
AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate. The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type ...
Min Son of Hanol IP & Law finds encouragement for developers of new chemical entity drugs after the rulings handed down in a battle between AstraZeneca and several generic pharmaceutical companies In ...
" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="359461" class="cbxwpbkmarktrig ...
The EMA's approval of Forxiga for chronic kidney disease gives AstraZeneca access to millions of patients in the EU. Forxiga's efficacy and this massive potential market should help the label ...
The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results